Sanofi (NASDAQ: SNY) — Company Overview, News & Financial Data
Sanofi is a global biopharmaceutical company developing innovative therapies across various medical needs and diseases.
SNY Sanofi
Company profile
Sanofi
Sanofi is a global biopharmaceutical company headquartered in Paris, France, specializing in the research, development, manufacturing, and marketing of therapeutic healthcare solutions worldwide. The company operates across key healthcare segments including immunology, vaccines, oncology, neurology, rare diseases, and general medicines. Sanofi maintains extensive global commercial networks, advanced research and development hubs, and biologic manufacturing infrastructure to deliver prescription therapies, vaccines, and consumer health products to healthcare providers and patients across international markets.
Snapshot
Public USOwnership
1973Year founded
~75,000Employees
Paris, FranceHead office
Loading Map...
Global footprint
Operations
All Locations
Republic of France
Products and/or services of Sanofi
- Immunology Therapies: Research, development, and global distribution of biologic medicines and monoclonal antibodies targeting chronic inflammatory conditions, severe asthma, atopic dermatitis, and autoimmune disorders across major international healthcare markets.
- Vaccines Manufacturing: Large-scale production and commercial supply of pediatric, seasonal influenza, meningococcal, and booster vaccines supplying healthcare systems, governments, and immunisation programs across Europe, the Americas, and global regions.
- Rare Disease Biopharmaceuticals: Specialized treatment portfolios addressing high-unmet-need genetic conditions, including lysosomal storage disorders, rare hematologic conditions, and metabolic diseases provided through specialized healthcare networks worldwide.
- Neurology and Neuroscience Treatments: Development and commercial distribution of advanced central nervous system therapeutics and neurodegenerative disease treatments, focusing on multiple sclerosis and relapsing-remitting neuroinflammatory diseases across international markets.
- Oncology and Immuno-Oncology Therapies: Targeted cancer therapeutics and tumor-targeted immunotherapies engineered for solid tumors and hematologic malignancies, manufactured across global biopharmaceutical production facilities for oncology treatment centers worldwide.
- General Medicines and Diabetes Care: Prescription pharmaceuticals, insulin formulations, cardiovascular therapies, and mature prescription brand portfolios distributed across hospital networks, retail pharmacies, and global primary care markets.
Sanofi executive team
- Belen Garijo LopezCEO & Director
- François-Xavier RogerExecutive VP & CFO
- Michael QuigleyChief Scientific Officer & Head of Research
- Thomas Kudsk LarsenHead of Investor Relations & General Medicines
- Jamie HaneyExecutive VP & General Counsel
- Pierre ChancelSenior Vice President of Global Diabetes and Senior Vice President of Global Marketing
- Veronique JailletExecutive VP & Interim Chief People Officer
- Fabrizio GaudiHead of Austrian, German & Swiss Operations
- Erik WallströmHead of Therapeutic Area - Neurology Development
- Thomas TriompheExecutive Vice President of Vaccines
Latest news about Sanofi
Sanofi Q3 sales rise 16.2% to €14.44 billion
United StatesSanofi and Cheplapharm announce strategic partnership for mature medicines portfolio
United StatesSanofi drops amlitelimab after phase 3 review
United StatesRegeneron and Sanofi secure historic seventh Japanese indication for Dupixent in bullous pemphigoid
United StatesTeva and Sanofi’s duvakitug clears key long-term hurdle in IBD race
United StatesSanofi to acquire Dynavax for $2.2B to scale adult vaccine portfolio
United States
Dividend history
Dividends per share paid by Sanofi , by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026(to date) | — | — | — | $2.4220 |
| FY2025 | — | — | — | $2.2120 |
| FY2024 | — | — | — | $2.0370 |
| FY2023 | — | — | — | $1.9030 |
| FY2022 | — | — | — | $2.0440 |
Key financials
Reported results for Sanofi , in EUR.
- Market cap
- 101.2B
- Revenue (TTM)
- 48.9B
- P/E ratio
- 22.2
- EPS (diluted, TTM)
- 1.9
- Dividend yield
- 9.8%
- Profit margin
- 8.1%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 46.7B | 9.6B | 7.8B | |
| 44.3B | 7.3B | 5.6B | |
| 41.6B | 7B | 5.4B | |
| 40.6B | 10.2B | 8.4B |